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Abstract: BACKGROUND Nut consumption has been associated with reduced inflammation, insulin
resistance, and oxidative stress. However, the influence on the prevalence and severity of non-alcoholic
fatty liver disease (NAFLD) has yet to be evaluated. METHODS 4655 subjects were included as part
of a colorectal carcinoma screening program (SAKKOPI) between 07/2010 and 07/2019 and analyzed
2020. Patients were characterized using biochemical and metabolic parameters, as well as a detailed
questionnaire on dietary habits. The diagnosis of NAFLD was established using abdominal ultrasound.
Consumption of nuts was graded as: no consumption or <1 time/week, 1-6 times/week, 1 time/day
and ฀2 times/day. RESULTS Mean age was 58.5±9.8years with a mean BMI of 26.5±4.7kg/m2. 2058
(44.2%) patients suffered from the metabolic syndrome, 2407 (51.6%) had arterial hypertension, 2287
(49.1%) showed prediabetes/diabetes, 1854 (39.4%) had dyslipidemia and 1984 patients (43.5%) were
diagnosed with NAFLD. Prevalence of metabolic syndrome (1219 [48.7%] vs. 605 [40.2%] vs. 189 [37.4%]
vs. 45 [31.7%], p<0.001) and NALFD (1184 [48.1%] vs. 594 [40.7%] vs. 158 [31.7%] vs. 48 [34.0%],
p<0.001). On multivariable logistic regression analysis adjusting for potential confounders and dietary
patterns, nut consumption ฀1time/day was inversely associated with NAFLD in the overall cohort (ad-
justed Odds ratio[aOR]: 0.719 [95%CI:0.558-0.926], p = 0.011). However, following subgroup analysis,
this inverse association was only confirmed in male patients (aOR: 0.589 [95%CI: 0.411-0.844], p = 0.004)
but not in females (aOR: 0.886 [95%CI: 0.616-1.275], p = 0.515). Moreover, patients who consumed
nuts 1-6 times/week had a significantly lower prevalence of advanced fibrosis (Fib-4 score >2.67: aOR:
0.551 [95%CI: 0.338-0.898], p = 0.017; Forns-Index >6.9: aOR: 0.585 [95%CI: 0.402-0.850], p = 0.005).
CONCLUSIONS Nut consumption might exert beneficial effects on the prevalence of NAFLD in males.
The negative association with advanced fibrosis warrants further investigation.
DOI: https://doi.org/10.1371/journal.pone.0244514
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Nut consumption has been associated with reduced inflammation, insulin resistance, and
oxidative stress. However, the influence on the prevalence and severity of non-alcoholic
fatty liver disease (NAFLD) has yet to be evaluated.
Methods
4655 subjects were included as part of a colorectal carcinoma screening program (SAK-
KOPI) between 07/2010 and 07/2019 and analyzed 2020. Patients were characterized
using biochemical and metabolic parameters, as well as a detailed questionnaire on dietary
habits. The diagnosis of NAFLD was established using abdominal ultrasound. Consumption
of nuts was graded as: no consumption or <1 time/week, 1–6 times/week, 1 time/day and
�2 times/day.
Results
Mean age was 58.5±9.8years with a mean BMI of 26.5±4.7kg/m2. 2058 (44.2%) patients
suffered from the metabolic syndrome, 2407 (51.6%) had arterial hypertension, 2287
(49.1%) showed prediabetes/diabetes, 1854 (39.4%) had dyslipidemia and 1984 patients
(43.5%) were diagnosed with NAFLD. Prevalence of metabolic syndrome (1219 [48.7%] vs.
605 [40.2%] vs. 189 [37.4%] vs. 45 [31.7%], p<0.001) and NALFD (1184 [48.1%] vs. 594
[40.7%] vs. 158 [31.7%] vs. 48 [34.0%], p<0.001). On multivariable logistic regression analy-
sis adjusting for potential confounders and dietary patterns, nut consumption�1time/day
was inversely associated with NAFLD in the overall cohort (adjusted Odds ratio[aOR]: 0.719
[95%CI:0.558–0.926], p = 0.011). However, following subgroup analysis, this inverse asso-
ciation was only confirmed in male patients (aOR: 0.589 [95%CI: 0.411–0.844], p = 0.004)
but not in females (aOR: 0.886 [95%CI: 0.616–1.275], p = 0.515). Moreover, patients who
consumed nuts 1–6 times/week had a significantly lower prevalence of advanced fibrosis
PLOS ONE







Citation: Semmler G, Bachmayer S, Wernly S,
Wernly B, Niederseer D, Huber-Schönauer U, et al.
(2020) Nut consumption and the prevalence and
severity of non-alcoholic fatty liver disease. PLoS
ONE 15(12): e0244514. https://doi.org/10.1371/
journal.pone.0244514




Published: December 31, 2020
Copyright: © 2020 Semmler et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement:Data cannot be
shared publicly because of institutional data policy
restrictions and national data policy restrictions
(www.ris.bka.gv.at). Data are available from the
General Hospital Oberndorf (contact via w.
ferlitz@kh-oberndorf.at) for researchers whomeet
the criteria for access to confidential data.
Funding: No funding was received for this study.
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Conclusions
Nut consumption might exert beneficial effects on the prevalence of NAFLD in males. The
negative association with advanced fibrosis warrants further investigation.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is regarded the emerging complex chronic liver dis-
ease of the 21st century, being significantly associated with increased cardiovascular and liver-
related risk [1–3]. Despite the increasing prevalence of NAFLD, no medical therapy has been
established. Thus, lifestyle and dietary interventions remain the cornerstone of treatment in
these patients.
Nuts are nutrient-dense food containing bioactive compounds regarded beneficial for
health: vegetable protein, unsaturated fatty acids, fiber, minerals, vitamins, tocopherols, phy-
tosterols, and polyphenols [4]. However, each nut type has a unique composition and different
amounts led to different health outcomes in interventional studies [5]. Importantly, most data
supporting a beneficial effect of nuts exist for almonds, walnuts, pistachios, and peanuts, fol-
lowed other nut types [5]. For instance, two randomized controlled trials could confirm the
lipid-lowering effect of 10/60g almonds/day in patients with coronary artery disease or type 2
diabetes mellitus (T2DM) [6, 7]. In large population-based studies not differentiating between
nut types [4], their consumption has been associated with reduced inflammation [8, 9] and
insulin resistance (IR) [10]. Moreover, a large body of evidence exists for the protective effect
of nuts on T2DM [11, 12], metabolic syndrome (MetS) [12–14], obesity [10, 12, 13] and arte-
rial hypertension [15]. Apart from these beneficial effects on aspects of the MetS, their role in
chronic liver disease and especially NAFLDmerits further investigation since inflammation,
oxidative stress and IR are considered key drivers of NAFLD [16–18]. Recently, a Chinese
study reported a significantly lower prevalence of NAFLD in patients consuming nuts�4
times/week [19]. However, another Chinese study confirmed this inverse association of
NAFLD and nut consumption only in a small subgroup of men when consuming�8.86g/day
[20] while data from Caucasian subjects addressing this topic is scarce. Therefore, we aimed to
further elucidate the role of nut consumption on the prevalence and severity of NAFLD.
Materials &methods
Patients and design
4655 individuals participating in a screening program for colorectal cancer (SAKKOPI)
between 07/2010 and 07/2019 were included in this analysis. Only patients with established
liver disease (i.e. viral hepatitis, autoimmune hepatitis, hereditary liver diseases) or with con-
sumption of a significant amount of alcohol (�2 drinks/day for females and�3 drinks/day for
males) were excluded from the analysis. All other patients without established liver disease
were included portraying a representative sample of the general population. Patients were
carefully characterized including laboratory and clinical data, and completed a detailed ques-
tionnaire on lifestyle and dietary habits. The study design and details of the clinical and bio-
chemical work-up of included subjects have been reported previously [21]. The study was
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approved by the “Ethikkommission für das Bundesland Salzburg” (approval no. 415-E/1262/2-
2010), and all patients gave written informed consent to participate.
Dietary assessment
Dietary data were collected using a food-frequency questionnaire (FFQ) which consisted of
69-items and was conducted in line with the questionnaire used in the SAPHIR [22], as well as
the EPIC study [23–25]. Patients completed the FFQ self-administered prior to all examina-
tions. Data on alcohol consumption, intake of fast-food, vegetables, fruits, sweets, red and pro-
cessed meat, white meat, fish, coffee and consumption of sugar-sweetened beverages (SSB)
and nuts were assessed. Specifically, nut consumption was reported semiquantitatively as no
consumption or<1 time (corresponding to ~10g) per week, 1–6 times per week, 1 time per
day and�2 times per day. Different types of nuts were not specified, and legume seeds were
included according to the interpretation of the patient. In order to quantify healthy eating pat-
terns, an adopted version of the “Alternate Healthy Eating Index” (AHEI-2010) was calculated
in accordance with the FFQ being available [26].
Definitions
The diagnosis of NAFLD was established using ultrasound being performed by experienced
operators. The liver was considered”normal” if the echogenicity was homogenous and similar
or slightly higher than that of the renal parenchyma. Portal veins and diaphragm had to be
visualized. The liver was considered as”fatty liver” when areas of significant increased echo-
genicity in relation to the renal parenchyma were found. The severity of sonographic steatosis
was not graded [21]. Advanced fibrosis (�F3) was assessed using Fib-4 score, NAFLD fibrosis
score (NFS) and Forns-Index [27, 28]. Cut-offs for advanced fibrosis were determined as pre-
viously described:>2.67 [27, 29] for Fib-4 score,>0.676 for NFS [30] and>6.9 for Forns-
Index [31]. Metabolic characterization included an oral glucose tolerance test (OGTT) as well
as measurement of fasting blood glucose and insulin measurement to assess IR. T2DM was
defined as either blood glucose level of�200mg/dl after 2 hours following oral glucose toler-
ance test (OGTT), fasting blood glucose (FBG)�125mg/dl, HbA1c�6.5%, or previously pre-
scribed antidiabetic medication including insulin. Impaired fasting glucose (IFG) was defined
as FBG 100-124mg/dl in non-diabetic individuals. Impaired glucose tolerance (IGT) was
defined as a blood glucose of 140-199mg/dl after 2 hours following OGTT in non-diabetic
individuals. Prediabetes was defined as IFG or IGT in non-diabetic individuals. Dysglycemia
was defined as presence of either prediabetes or T2DM. Components of the MetS were defined
according to the revised definition of the International Diabetes Federation (2005) [32]. Vis-
ceral obesity was defined as waist circumference (WC)�80cm for women and�94cm for
men. Hypertension was defined as a blood pressure (BP)�130/85mmHg or previous prescrip-
tion of any antihypertensive drug. Dyslipidemia was defined as high-density lipoprotein cho-
lesterol (HDL-C)<40mg/dl in males or<50mg/dl in females, triglycerides�150mg/dl or
previously prescribed lipid lowering drugs. The MetS was defined as at least three of the fol-
lowing components: Visceral adiposity, hypertension, FBG�100mg/dl or antidiabetic therapy,
HDL-C<40mg/dl in males or<50mg/dl in females or antilipidemic drugs, triglycerides
�150mg/dl or antilipidemic drugs. Of note, levels of systolic BP, FBG, blood glucose following
OGTT, HbA1c, HOMA-IR, triglycerides, cholesterol, HDL-C and low-density lipoprotein
cholesterol (LDL-C) were only considered for comparison in the absence of specific medica-
tion. Chronic coronary syndrome (CCS) was defined as history of myocardial infarction, coro-
nary artery disease, coronary artery bypass graft or coronary stent.
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Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics 26 (SPSS Inc., Armonk, New
York, USA) and GraphPad Prism 8 (GraphPad Software, La Jolla, California, USA) in 2020.
Continuous variables were reported as mean ± standard deviation or median (interquartile
range [IQR]) depending on their distribution, while categorical variables were shown as num-
bers and proportions of patients (%). Comparisons of continuous variables were performed
using Student’s t-test, Mann-Whitney U test or Kruskal-Wallis test, as applicable. Group com-
parisons were performed applying Chi-squared test. Logistic regression analysis was per-
formed to investigate the associations of nut consumption on the presence of NAFLD and the
presence of advanced fibrosis, using the group with the lowest nut consumption as reference
category. Since the number of individuals in group 4 was too limited to draw firm conclusions,
groups 3 and 4 were combined for logistic regression analyses. P-values were calculated for
each group compared to the reference group, as well as P-values for linear trends. Multivari-
able models were adjusted for potential confounders including sex, age and BMI, MetS, and
dietary parameters such as alcohol consumption, intake of fast-food, vegetables, fruits, sweets,
red and processed meat, white meat, fish, coffee and consumption of SSB, as previously
described [19, 20]. Analyses on Fib-4 score and Forns-Index were not adjusted for age since
this variable is included in these indices. Subgroup analyses were performed in patients with




Overall, 4655 individuals were included with a slight preponderance of males (n = 2395,
51.5%), and a mean age of 58.5±9.8. 2058 patients (44.2%) suffered from the MetS with 3278
(76.9%) suffering from visceral obesity, 2407 (51.6%) from hypertension, 2287 (49.1%) from
T2DM or prediabetes, and 1854 (39.8%) from dyslipidemia. Additionally, 280 (6.0%) individu-
als had previously diagnosed CCS, 152 (3.3%) peripheral arterial disease (PAD) and 148
(3.2%) had previously suffered from stroke. 2502 patients (53.7%) did not consume nuts or
consumed nuts<1 time/week, 1506 patients (32.4%) consumed nuts 1–6 times/week, 505
patients (10.8%) consumed nuts 1 time/day (once daily) and 142 patients (3.1%)�2 times/day
(at least twice daily).
Nut consumption, metabolic syndrome and cardiovascular health
The prevalence of the MetS declined with more frequent nut consumption (48.7% vs. 40.2%
vs. 37.4% vs. 31.7%, p<0.001). Importantly, this trend was also observed for all singular com-
ponents (Table 1). Similarly, the proportion of patients suffering from cardiovascular diseases
decreased with increasing nut consumption: 7.5% vs. 4.4% vs. 4.0% vs. 3.5% for CCS
(p<0.001), 4.3% vs. 2.0% vs. 2.6% vs. 2.1% for PAD (p = 0.001) and 4.0% vs. 2.1% vs. 2.8% vs.
1.4% for stroke (p = 0.005).
Dietary patterns including consumption of alcohol, fast-food, fruits, vegetables, sweets, cof-
fee, SSBs, red meat and fish were significantly different among these groups with less frequent
fast-food consumption and consumption of red or processed meat and a higher consumption
of fruits, vegetables and coffee in patients with more frequent nut consumption (Table 2). Con-
secutively, these subjects had higher scores in the adopted version of the AHEI-2010 (42.4±8.7
vs. 49.3±8.2 vs. 57.6±7.8 vs. 60.6±8.2 points, p<0.001).
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Nut consumption and NAFLD
The prevalence of NAFLD decreased among nut consumption groups: 1184 patients (48.1%)
with nut consumption<1time/week, 594 patients (40.7%) with 1–6 times/week, 158 (31.7%)
with 1time/day and 48 patients (34.0%) with�2times/day were diagnosed with NAFLD
(p<0.001, Table 3). The prevalence of a Fib-4 score of>2.67 indicative for advanced fibrosis
was significantly different among groups (3.9% vs. 2.0% vs. 3.2% vs. 3.5%, p = 0.014), concor-
dantly to the prevalence of NFS>0.676 (5.6% vs. 1.9% vs. 3.0% vs. 2.4%, p<0.001) and Forns-
Index>6.9 (6.9% vs. 3.4% vs. 4.2% vs. 2.1%, p<0.001). Finally, patients had less elevated levels
of gamma-glutamyl transferase (GGT; median GGT/sex-specific upper limit of normal: 0.69
[IQR: 0.46–1.18] vs. 0.64 [0.44–1.08] vs. 0.56 [0.38–0.87] vs. 0.51 [0.37–0.82], p<0.001).
On multivariable logistic regression analysis adjusting for potential confounders, patients
consuming nuts�1time/day had a significantly lower risk for NAFLD (aOR: 0.589 [95%CI:
0.558–0.926], p = 0.011) when compared to those within the lowest group (Table 4). However,
a linear trend across all groups was observed (p = 0.016). Interestingly, patients consuming
Table 1. Patient characteristics in the overall cohort and compared among patients grouped according to their frequency of nut consumption.
Patient characteristics All patients, n = 4655 <1 time/week, n = 2502 1–6 times/week, n = 1506 1 time/day, n = 505 �2 times/day, n = 142 P value
Age, years 58.5±9.8 58.8±10.2 57.6±9.2 59.8±8.7 58.2±8.8 <0.001
Male sex 2395 (51.5%) 1360 (54.4%) 766 (50.9%) 209 (41.4%) 60 (42.3%) <0.001
Obesity 1068 (22.9%) 661 (26.5%) 302 (20.1%) 77 (15.2%) 29 (19.7%) <0.001
BMI, kg/mg2 26.5±4.7 27.6±4.9 26.7±4.5 25.9±4.2 25.9±4.5 <0.001
Visceral obesity� 3278 (76.9%) 1814 (79.9%) 1050 (75.1%) 331 (71.3%) 83 (62.4%) <0.001
WC, cm� 96.3±13.3 98.1±13.6 95.2±12.6 92.5±12.3 92.2±14.2 <0.001
Metabolic syndrome 2058 (44.2%) 1219 (48.7%) 605 (40.2%) 189 (37.4%) 45 (31.7%) <0.001
Hypertension 2407 (51.6%) 1776 (71.0%) 972 (64.5%) 341 (67.5%) 94 (66.2%) <0.001
T2DM/prediabetes 2287 (49.1%) 1334 (53.3%) 679 (45.1%) 226 (44.8%) 48 (33.8%) <0.001
T2DM 638 (13.7%) 422 (16.9%) 151 (10.0%) 47 (9.3%) 18 (12.7%) <0.001
Prediabetes 1649 (35.4%) 912 (36.5%) 528 (35.1%) 179 (35.4%) 30 (21.1%) 0.003
IFG 1365 (29.3%) 753 (30.1%) 446 (29.6%) 139 (27.5%) 27 (19.0%) 0.001
IGT 638 (13.7%) 362 (14.5%) 193 (12.8%) 76 (15.0%) 7 (4.9%) <0.001
FBG, mg/dl 98±20 99±15 98±27 96±11 96±18 0.008
OGTT after 2h, mg/dl 122±37 125±39 119±33 122±33 119±39 <0.001
HbA1c, % 5.5±0.4 5.6±0.5 5.5. ±0.4 5.5±0.4 5.5±0.4 <0.001
HOMA-IR, points 1.67 (1.11–2.62) 1.79 (1.15–2.81) 1.63 (1.13–2.53) 1.46 (1.00–2.30) 1.46 (0.90–2.30) <0.001
Dyslipidemia 1854 (39.8%) 1083 (43.3%) 553 (36.7%) 174 (14.5%) 44 (31.0%) <0.001
Triglycerides, mg/dl 102 (76–142) 106 (78–148) 101 (74–140) 93 (72–129) 88 (67–126) <0.001
Hypertriglyceridemia 879 (18.9%) 507 (20.3%) 281 (18.7%) 72 (14.3%) 19 (13.4%) <0.001
Cholesterol, mg/dl 224±41 223±43 226±40 225±39 222±41 0.333
Hypercholesterinemia 2857 (61.4%) 1463 (58.5%) 991 (65.8%) 315 (62.4%) 88 (62.0%) 0.040
HDL-C, mg/dl 60±17 59±17 60±18 62±17 64±17 <0.001
LDL-C, mg/dl 145±37 145±38 147±37 145±36 140±37 0.244
CCS 280 (6.0%) 188 (7.5%) 67 (4.4%) 20 (4.0%) 5 (3.5%) <0.001
PAD 152 (3.3%) 106 (4.3%) 30 (2.0%) 13 (2.6%) 3 (2.1%) 0.001
Stroke 148 (3.2%) 100 (4.0%) 32 (2.1%) 14 (2.8%) 2 (1.4%) 0.005
� Data available in 4265 patients.
Abbreviations: BMI–body mass index; CCS–chronic coronary syndrome; FBG–fasting blood glucose; HOMA-IR–Homeostasis Model Assessment for Insulin
Resistance; IFG–impaired fasting glucose; IGT–impaired glucose tolerance; OGTT–oral glucose tolerance test; PAD–peripheral artery disease; T2DM–type 2 diabetes
mellitus; WC–waist circumference.
https://doi.org/10.1371/journal.pone.0244514.t001
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nuts 1–6 times/week had a significantly lower odds of advanced fibrosis (Fib-4 score>2.67:
aOR: 0.551 [95%CI: 0.338–0.898], p = 0.017; Forns-Index>6.9: aOR: 0.585 [95%CI: 0.402–
0.850], p = 0.005) which was more pronounced in the subgroup of NAFLD patients (Fib-4
score>2.67: aOR: 0.275 [95%CI: 0.112–0.678], p = 0.005; Forns-Index>6.9: aOR: 0.384 [95%
CI: 0.226–0.653], p<0.001). In order to identify potential reasons for these inverse associa-
tions, markers of inflammation were compared among subgroups of nut-consumption. Inter-
estingly, subjects with more frequent nut consumption had significantly lower levels of C-
reactive protein concentrations (0.20 [IQR: 0.10–0.40] vs. 0.17 [0.10–0.31] vs. 0.15 [0.08–0.30]
vs. 0.11 [0.08–0.27] mg/dl, p<0.001) and ferritin concentrations (134 [71–231] vs. 114 [63–
193] vs. 103 [54–178] vs. 89 [42–159] μg/l, p<0.001; S1 Table in S1 File). Of note, when
Table 2. Dietary patterns compared among patients grouped according to their frequency of nut consumption.
Patient characteristics <1 time/week, n = 2502 1–6 times/week, n = 1506 1 time/day, n = 505 �2 times/day, n = 142 P value
Alcohol consumption�3 times/week 31.0% 37.5% 29.7% 32.4% <0.001
Fast food�1/month 51.0% 57.9% 41.5% 34.8% <0.001
Daily fruit intake 59.5% 71.8% 84.5% 84.1% <0.001
Daily vegetable intake 63.8% 75.4% 86.2% 86.3% <0.001
Daily sweets intake 30.8% 37.3% 41.5% 39.1% <0.001
Daily coffee intake 48.6% 58.4% 53.1% 54.9% <0.001
Daily SSB intake 10.2% 13.9% 10.3% 9.9% 0.002
Red meat�2days/week 71.3% 65.4% 55.7% 46.6% <0.001
White meat�2days/week 32.5% 32.8% 31.9% 27.5% 0.663
Fish�1day/week 76.4% 86.8% 83.8% 85.5% <0.001
Adopted AHEI-2010� 42.4±8.7 49.3±8.2 57.6±7.8 60.6±8.2 <0.001
� The percentage of trans-Isomers of fatty acids and polyunsaturated fatty acids from total energy intake could not be sufficiently calculated owing to the nature of our
FFQ. Therefore, these variables could not be calculated leading to a maximum score of 90 points.
Abbreviations: SSB–sugar-sweetened beverages.
https://doi.org/10.1371/journal.pone.0244514.t002
Table 3. Distribution of hepatic steatosis as well as non-invasive scores for hepatic fibrosis compared among patients grouped according to their frequency of nut
consumption.
Patient characteristics <1 time/week, n = 2502 1–6 times/week, n = 1506 1 time/day, n = 505 �2 times/day, n = 142 P value
NAFLD� 1184 (48.1%) 594 (40.7%) 158 (31.7%) 48 (34.0%) <0.001
Fib-4 score 1.16 (0.89–1.53) 1.12 (0.88–1.43) 1.17 (0.95–1.58) 1.19 (1.00–1.54) <0.001
>2.67 96 (3.9%) 30 (2.0%) 16 (3.2%) 5 (3.5%) 0.014
>3.25 58 (2.3%) 20 (1.3%) 10 (2.0%) 1 (0.7%) 0.108
NFS -1.64 (-2.41-[-0.70]) -1.88 (-2.51-[-1.17]) -1.81 (-2.49-[-0.93]) -1.81 (-2.30-[-0.83]) <0.001
>0.676 64 (5.6%) 17 (1.9%) 9 (3.0%) 2 (2.4%) <0.001
Forns-Index 4.51±1.55 4.29±1.36 4.37±1.37 4.31±1.31 <0.001
>6.9 171 (6.9%) 51 (3.4%) 21 (4.2%) 3 (2.1%) <0.001
ALT/ULN 0.50 (0.38–0.71) 0.50 (0.37–0.69) 0.49 (0.37–0.66) 0.49 (0.37–0.58) 0.055
AST/ULN 0.60 (0.51–0.74) 0.60 (0.49–0.71) 0.57 (0.49–0.71) 0.60 (0.51–0.66) 0.056
GGT/ULN 0.69 (0.46–1.18) 0.64 (0.44–1.08) 0.56 (0.38–0.87) 0.51 (0.37–0.82) <0.001
� Data available in 4563 patients.
ULN was regarded as 50 U/L for ALT and AST in male patients and 35 U/L in female patients.
Abbreviations: ALT–alanine aminotransferase; AST–aspartate aminotransferase; GGT–gamma-glutamyl transferase; NAFLD–non-alcoholic fatty liver disease; NFS–
NAFLD fibrosis score; ULN–upper limit of normal.
https://doi.org/10.1371/journal.pone.0244514.t003
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replacing dietary patterns with the adopted AHEI-2010 for regression analyses, there was no inde-
pendently association with NAFLD (aOR per point: 0.992 [95%CI: 0.984–1.000], p = 0.063).
Gender differences
In order to address gender differences with regard to nut consumption, we performed gender-
specific subgroup analyses in males and females. Differences in baseline characteristics are dis-
played in S2 Table in S1 File. The negative association with NAFLD was even more pro-
nounced in males consuming nuts�1time/day (aOR: 0.589 [95%CI: 0.411–0.844], p = 0.004).
However, it could not be confirmed in female patients (aOR: 0.886 [95%CI: 0.616–1.275],
p = 0.516; S3 Table in S1 File). Although a trend for decreased odds of having advanced fibrosis
as assessed by Fib-4 score>2.67 was evident both in males and females consuming nuts 1–6
times/week, a significant associated could only be confirmed in males applying the Forns-
index>6.9 (aOR: 0.610 [95%CI: 0.402–0.924], p = 0.020). Again, the adopted AHEI-2010 was
not associated with NAFLD in males (aOR: 0.992, [95%CI: 0.982–1.003], p = 0.156) or females
(aOR: 0.994, [95%CI: 0.982–1.007], p = 0.347).
Discussion
Nuts have previously been associated with a reduced risk for MetS, especially T2DM, hyper-
tension and obesity [11–14], and reduced risk for cardiovascular disease and death [33], while
recently, a potentially protective effect on the prevalence of NAFLD was proposed in two
Asian cohorts [19, 20]. In our study, we show that nut consumption at least once a day was
associated with a significantly decreased risk for NAFLD while any consumption of nuts was
linked to a lower prevalence of advanced fibrosis in NAFLD subjects. Moreover, we confirm
other study results showing a lower prevalence of MetS and cardiovascular diseases among
nut-consumers [13, 14].
Generally speaking, nuts are rich in monounsaturated and polyunsaturated fatty acids
(PUFA), vegetable protein, fibers, folate, vitamins (e.g. tocopherols) and minerals (e.g. copper),
Table 4. Odds Ratio (OR) and 95% confidence interval (95%CI) for NAFLD and advance fibrosis among groups of nut-consumers using binary logistic regression
analyses adjusted for potential confounders.
Overall cohort NAFLD
aOR (95% CI) P value P value for linear trend aOR (95% CI) P value P value for linear trend
NAFLD <1 time/week reference reference 0.016 - - -
1–6 times/week 0.923 (0.770–1.106) 0.384 - - -
�1 time/day 0.719 (0.558–0.926) 0.011 - - -
Fib-4 score>2.67 <1 time/week reference reference 0.110 reference reference 0.099
1–6 times/week 0.551 (0.338–0.898) 0.017 0.275 (0.112–0.678) 0.005
�1 time/day 0.780 (0.427–1.423) 0.418 0.844 (0.337–2.110) 0.716
Forns-Index>6.9 <1 time/week reference reference 0.002 reference reference 0.001
1–6 times/week 0.585 (0.402–0.850) 0.005 0.384 (0.226–0.653) <0.001
�1 time/day 0.533 (0.304–0.934) 0.028 0.450 (0.198–1.023) 0.057
Analyses were based on the overall cohort and NAFLD patients.
Displayed OR are adjusted for sex, age, BMI, metabolic syndrome, hepatic steatosis, alcohol consumption, intake of fast-food, vegetables, fruits, sweets, red and
processed meat, white meat, fish, coffee and consumption of SSB. OR for Fib-4 score and Forns-Index were not adjusted for age since this variable is included in these
indices.
Abbreviations: aOR–adjusted Odds ratio; NAFLD–non-alcoholic fatty liver disease; SSB–sugar-sweetened beverage; T2DM–type 2 diabetes mellitus; 95%CI– 95%
confidence interval.
https://doi.org/10.1371/journal.pone.0244514.t004
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among other bioactive compounds including carotenoids, phytosterols and polyphenolic com-
pounds including flavonoids [5, 34–36]. Specifically, folate has been associated with counter-
acting atherothrombotic properties of homocysteine [37] while phytosterols might interfere
with cholesterol absorption [4]. Tocopherol (i.e. vitamin E) and polyphenols have protective
properties against free radicals and oxidative stress [4, 38], with flavonoid intake being linked
to reduced all-cause, cardiovascular and cancer mortality [39], and tocopherol being widely
used off-label to treat NAFLD due to its beneficial effects on liver enzyme elevations and his-
tology improvement [40]. Other important components are omega-3-fatty-acids: Their dietary
supplementation has recently been associated with reduced triglyceride levels and cardiopro-
tective effects [41, 42]. Carotenoids—especially β-carotene–have also been attributed certain
antioxidative effects, and recent study results showed that consuming high amounts of carot-
enoids lowered the risk of NAFLD [43], and improved lipid profiles in an animal models [44].
Finally, nondigestible components of nuts act as probiotics providing beneficial substrates for
the gut microbiota [45]. Thus, several components and their synergetic interaction could
explain a potential favorable effect on human physiology [4]. Interestingly, copper deficiency
has previously been linked to disturbed iron homeostasis in NAFLD [46], potentially aggravat-
ing the natural course of NAFLD [47, 48]. Although copper supplementation by nut consump-
tion might counteract harmful effects of copper deficiency in NAFLD, considerable variations
in copper content of different nuts need to be considered.
Recently, Zhang et al [19] reported on a large retrospective cohort of 23915 patients exclud-
ing those with cardiovascular diseases or cancer, and found a significantly lower prevalence of
NAFLD in patients consuming nuts�4 times/week, being equivalent to�200-240g/week.
However, a smaller Chinese cohort study including 1068 patients, could only reproduce this
finding in males within the highest quartile of nut intake [20]. Together, these studies add up
to evidence from small cohort studies (<400 patients) reporting benefits for subjects with
NAFLD [49–51]. Although we confirm these data in a representative cohort of Caucasian indi-
viduals, subgroup analyses could only reproduce this inverse association in male individuals.
This is interesting since our findings go in line with previous studies reporting an association
only in males [20, 49]. However, we can only speculate on potential explanations: First, the
benefit of nut consumption might be better discernible in men on the background of more
prevalent NAFLD and more pronounced MetS components [52]. Moreover, men usually have
larger visceral fat mass, being associated with a more pro-inflammatory profile [53], which
directly releases free-fatty acids into the portal vein, thereby promoting fat-accumulation in
the liver [54]. Second, women are considered to have a higher awareness for healthy nutrition
[55], which is also indicated by a higher prevalence of female gender in more frequent nut con-
sumption groups in our study. Thus, the effect of nuts could be mitigated by other healthy die-
tary patterns.
To the best of our knowledge, this is the first study which proposes a beneficial effect of
nuts on the prevalence of advanced fibrosis in patients with NAFLD. Although we cannot
explain why the effect on fibrosis seems to start already when consuming nuts less frequently
(i.e. 1–6 times/week), our data allow speculation that the beneficial effect on subsequent
inflammation in the liver might already be evident at lower levels. Of note, we show that
inflammation markers gradually decline with more frequent nut consumption, presumably
indicating less inflammation, being the most important driver of fibrogenesis [56]. However,
we acknowledge that blood inflammation markers may not fully mirror inflammation in the
liver.
Additionally, it is unclear whether the beneficial effect of nuts follows a linear or U-shaped
curve. Despite the large number of favorable bioactive compounds, nuts are also rich in fat
and calories [4], consequently boosting one’s energy intake if consumed on a daily basis. This
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is supported by similar cholesterol and LDL-C levels among our patient groups independent
from their amount of nut consumption. Thus, a frequent consumption might in some terms
limit the beneficial effect of nuts’ healthy components.
This study has strengths with regard to investigating the link between fatty liver and dietary
habits. To begin with, patients underwent careful metabolic and characterization in the
absence of clinical suspicion or indication for diagnostic work-up. Due to the coincidence that
endoscopies are mainly performed at the General Hospital Oberndorf in the local catchment
area, we are confident that we could obtain a representative sample of the general population
at risk for NAFLD (~60 years of age). Importantly, the fact that no other regulations existed on
which patients were included in the study (e.g. type of insurance or comorbidities), mitigated
selection bias, which is often introduced in other liver-centered studies.
However, several limitations need to be considered when interpreting our results. To begin
with, we acknowledge that nut types are unique in their composition and their effect on
human health [5] especially when prepared differently (e.g. roasted, cooked, salted). However,
we did not specifically assess nut types and preparation. Thus, we cannot exclude that differ-
ences in preparation (e.g. with chocolate in candy or baked goods) mitigate the associations
reported in this study, and might decrease the study’s impact. This is especially true for pea-
nuts, which are commonly misclassified as nuts despite being legumes, which is likely to have
occurred in our study. However, from the patient’s point-of-view, specifying different nut
types would increase uncertainties on true consumption since their frequency again decreases,
and overreporting. From a statistical point of view, it would decrease statistical power. There-
fore, we could not dissect potentially diverse effects of different nut types. Secondly, dietary
habits assessed using FFQ are always patient-reported and therefore subject to response and
recall bias: The correctness of the answers given by the patients can never be verified, nor can
the correct recall from the patients’ memory be verified. Also, FFQ require literacy and can be
subject to overreporting [57].
Data from our study indicate that nuts are part of a healthier dietary pattern with significant
differences among several healthy or unhealthy food types (Table 2). Demonstrated by a higher
score in the AHEI-2020, these patients adhere to a healthier diet, which could accentuate the
associations which were attributed to nut consumption. Nevertheless, the inverse association
of nut consumption with NAFLD and advanced fibrosis remained significant after adjusting
for several confounding food types such as red meat, coffee, and SSB, which have been linked
to NAFLD previously [58–62]. Noteworthy, these significant dietary differences between
patients consuming nuts and those who do not can also be observed in the majority of studies
investigating the role of nuts [14], especially in those investigating NAFLD [19, 20].
Specific limitations of this study include the retrospective design which can only generate
associations, but never causalities. Unfortunately, physical activity was only inconsistently
reported and therefore could not be included as a covariate in regression models. Finally,
NAFLD was diagnosed by abdominal ultrasound in our study. This is a limitation since
hepatic steatosis can only be graded qualitatively, with particular weakness for lower degrees of
liver fat. Therefore, a modest effect of any nut consumption might not be detected as a resolu-
tion of hepatic steatosis in our study.
Nevertheless, we demonstrate an inverse association of nut consumption with the preva-
lence of NAFLD in a large European cohort. In line with the literature, we confirm a stronger
association in male gender. Moreover, we are the first to report a potentially favorable effect
on the prevalence of advanced fibrosis. Our findings support recommendations for regular
nut consumption as part of a Mediterranean diet, especially in patients with NAFLD [63].
Future dietary interventional studies investigating lipid-lowering and anti-inflammatory
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properties of nuts in patients with NAFLD are needed to investigate the full potential of this





Conceptualization: Georg Semmler, Christian Datz.
Data curation: Georg Semmler, Sebastian Bachmayer, Sarah Wernly, Ursula Huber-Schö-
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33. Guasch-Ferré M, Liu X, Malik VS, Sun Q,Willett WC, Manson JE, et al. Nut Consumption and Risk of
Cardiovascular Disease. Journal of the American College of Cardiology. 2017; 70(20):2519–32. https://
doi.org/10.1016/j.jacc.2017.09.035 PMID: 29145952
34. Souza RG, Gomes AC, NavesMM, Mota JF. Nuts and legume seeds for cardiovascular risk reduction:
scientific evidence and mechanisms of action. Nutrition reviews. 2015; 73(6):335–47. https://doi.org/10.
1093/nutrit/nuu008 PMID: 26011909
35. Bolling BW, McKay DL, Blumberg JB. The phytochemical composition and antioxidant actions of tree
nuts. Asia Pacific journal of clinical nutrition. 2010; 19(1):117–23. PMID: 20199996
36. Kornsteiner M,Wagner K-H, Elmadfa I. Tocopherols and total phenolics in 10 different nut types. Food
Chemistry. 2006; 98(2):381–7.
37. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. The New England journal of medicine.
1998; 338(15):1042–50. https://doi.org/10.1056/NEJM199804093381507 PMID: 9535670
38. TaşNG, Gökmen V. Phenolic compounds in natural and roasted nuts and their skins: a brief review.
Current Opinion in Food Science. 2017; 14:103–9.
39. Bondonno NP, Dalgaard F, KyrøC, Murray K, BondonnoCP, Lewis JR, et al. Flavonoid intake is associ-
ated with lower mortality in the Danish Diet Cancer and Health Cohort. Nature Communications. 2019;
10(1):3651. https://doi.org/10.1038/s41467-019-11622-x PMID: 31409784
40. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, Vitamin
E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2010; 362(18):1675–
85.
41. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduc-
tion with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2018; 380(1):11–
22. https://doi.org/10.1056/NEJMoa1812792 PMID: 30415628
42. Skulas-Ray AC,Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3
Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart
Association. Circulation. 2019; 140(12):e673–e91. https://doi.org/10.1161/CIR.0000000000000709
PMID: 31422671
43. Christensen K, Lawler T, Mares J. Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among
US Adults, NHANES 2003(-)2014. Nutrients. 2019; 11(5).
44. Elvira-Torales LI, Martin-Pozuelo G, Gonzalez-Barrio R, Navarro-Gonzalez I, Pallares FJ, Santaella M,
et al. Ameliorative Effect of Spinach on Non-Alcoholic Fatty Liver Disease Induced in Rats by a High-
Fat Diet. International journal of molecular sciences. 2019; 20(7). https://doi.org/10.3390/ijms20071662
PMID: 30987167
45. Lamuel-Raventos RM, OngeMS. Prebiotic nut compounds and humanmicrobiota. Critical reviews in
food science and nutrition. 2017; 57(14):3154–63. https://doi.org/10.1080/10408398.2015.1096763
PMID: 27224877
46. Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L, et al. Copper availability contributes to
iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology. 2008; 135(2):680–8.
https://doi.org/10.1053/j.gastro.2008.04.007 PMID: 18505688
47. Datz C, Müller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva endocrinologica.
2017; 42(2):173–83. https://doi.org/10.23736/S0391-1977.16.02565-7 PMID: 27834478
48. Aigner E, Strasser M, Haufe H, Sonnweber T, Hohla F, Stadlmayr A, et al. A role for low hepatic copper
concentrations in nonalcoholic Fatty liver disease. The American journal of gastroenterology. 2010; 105
(9):1978–85. https://doi.org/10.1038/ajg.2010.170 PMID: 20407430
PLOS ONE Nuts and NAFLD
PLOSONE | https://doi.org/10.1371/journal.pone.0244514 December 31, 2020 12 / 13
49. Han JM, Jo AN, Lee SM, Bae HS, Jun DW, Cho YK, et al. Associations between intakes of individual
nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. Journal of
gastroenterology and hepatology. 2014; 29(6):1265–72. https://doi.org/10.1111/jgh.12520 PMID:
24955455
50. Kalafati IP, Dimitriou M, Borsa D, Vlachogiannakos J, Revenas K, Kokkinos A, et al. Fish intake inter-
acts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study. European journal
of nutrition. 2019; 58(4):1463–73. https://doi.org/10.1007/s00394-018-1675-4 PMID: 29574608
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